Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Clinical Outcomes
100%
Dose Adjustment
100%
Dose-adjusted EPOCH-R
100%
Triple-hit Lymphoma
100%
Prednisone
20%
Progression-free Survival
20%
Multivariate Analysis
20%
Overall Survival
20%
Dose Escalation
20%
Clinical Data
20%
Rituximab
20%
Hematotoxicity
20%
Survival Outcomes
20%
Adult Age
20%
Cumulative Dose
20%
Doxorubicin
20%
Cyclophosphamide
20%
R-CHOP
20%
Double-hit Lymphoma
20%
4-cycle
20%
R-EPOCH
20%
Chemotherapy Dose
20%
Induction Dose
20%
Dose Intensification
20%
Biochemistry, Genetics and Molecular Biology
Overall Survival
100%
Multivariate Analysis
100%
Progression Free Survival
100%
Rituximab
100%
Cyclophosphamide
100%
Drug Dose Intensification
100%
Doxorubicin
100%
Prednisone
100%
Medicine and Dentistry
Cyclophosphamide Plus Doxorubicin Plus Etoposide Plus Prednisolone Plus Rituximab Plus Vincristine
100%
Progression Free Survival
16%
Overall Survival
16%
Rituximab
16%
Doxorubicin
16%
Cyclophosphamide
16%
Prednisone
16%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
16%
Vincristine
16%
Drug Dose Intensification
16%
Multivariate Analysis
16%
Pharmacology, Toxicology and Pharmaceutical Science
Cyclophosphamide Plus Doxorubicin Plus Etoposide Plus Prednisolone Plus Rituximab Plus Vincristine
100%
Prednisone
16%
Progression Free Survival
16%
Overall Survival
16%
Chemotherapy
16%
Rituximab
16%
Doxorubicin
16%
Cyclophosphamide
16%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
16%
Vincristine
16%
Immunology and Microbiology
Cyclophosphamide Plus Doxorubicin Plus Etoposide Plus Prednisolone Plus Rituximab Plus Vincristine
100%
Overall Survival
16%
Rituximab
16%
Progression Free Survival
16%
Prednisone
16%
Cyclophosphamide
16%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
16%
Drug Dose Intensification
16%